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Malignant tumours of the gastrointestinal (GI) tract are common,
leading to premature death in a high proportion of cases. 5-
Fluorouracil (5-FU)-based chemotherapy for advanced disease is
superior to best supportive care in colorectal and gastric cancer
(Nordic Gastrointestinal Tumour Adjuvant Therapy Group, 1992;
Murad et al, 1993). Combination chemotherapy for both upper and
lower GI tract cancers is now producing increased response rates
with acceptable toxicity (Webb et al, 1997; Ross et al, 1997). New
active agents have recently been developed, and attention is
focusing on combinations of these in an attempt further to improve
response rates and survival. Irinotecan hydrochloride, via its active
metabolite SN-38, is an inhibitor of DNA topoisomerase I, an
enzyme essential for DNA transcription and commonly overex-
pressed in colorectal adenocarcinomas (Giovanella et al, 1989). It
has in vitro activity against a number of different cell lines
(Shimada et al, 1994), and demonstrated activity against a variety
of tumours including colorectal and gastric cancers in phase II
trials. Irinotecan also displays non cross-resistance to 5-FU
(Rougier et al, 1997) and is approved as a single agent for the
treatment of 5-FU-refractory colorectal cancer. Dose-limiting toxi-
cities (DLT) are myelosuppression and delayed diarrhoea, which is
unpredictable and may be life-threatening (Armand, 1996). Early
use of high-dose loperamide can minimize the danger from this
effect (Abigerges et al, 1994), and it appears that neutropaenia is
the true DLT. Raltitrexed is a specific thymidylate synthase
inhibitor (Jackman et al, 1991). It has equivalent response rates to
5-FU plus leucovorin (LV) in advanced colorectal cancer, with
reduced antiproliferative toxicity (Cunningham et al, 1996). DLT
are gastrointestinal (diarrhoea) and haematological (neutropenia
and thrombocytopenia), as well as lethargy (Clarke et al, 1996;
Grem et al, 1999). In vitro studies with irinotecan and raltitrexed
demonstrate highly sequence-specific synergy (Aschele et al,
1998). The primary objectives of this study were to determine the
maximum tolerated doses (MTD) of the two drugs given as short
infusions every 3 weeks and to determine the toxic effects and
DLT of the combination. Secondary objectives were to measure
the pharmacokinetics of irinotecan, SN-38 and raltitrexed, to
assess the anti-tumour effect of the combination and to recom-
mend a safe dose for phase II evaluation.
METHODS
Definitions
DLT was defined as any grade 3 or 4 non-haematological toxicity
(except alopecia) following cycle 1; grade 4 neutropenia or grade
3–4 neutropenia associated with fever (> 38°C) or sepsis; grade 4
thrombocytopenia or any grade of thrombocytopenia associated
with haemorrhage. MTD was defined as the dose level at which
50% of patients experienced the same DLT.
Eligibility
Eligibility criteria were as follows: histologically confirmed
advanced GI tract adenocarcinoma; life expectancy ³ 12 weeks;
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Summary To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as
sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric)
entered this open label dose-escalation study. For the first five dose levels patients received irinotecan 175–350 mg m–2 followed by
raltitrexed 2.6 mg m–2. Level VI was irinotecan 350 mg m–2 plus raltitrexed 3.0 mg m–2, level VII was irinotecan 400 mg m–2 plus raltitrexed 
2.6 mg m–2; 261 courses were administered. Only one patient at dose levels I–V experienced DLT. At level VI, 5/12 patients experienced DLT:
one had grade 3 diarrhoea and lethargy, one had grade 4 diarrhoea and one had lethargy alone. Two others had lethargy caused by disease
progression. There was no first-cycle neutropenia. At level VII, 3/6 patients experienced dose-limiting lethargy, one also had grade 3
diarrhoea. Dose intensity fell from over 90% for both drugs at level VI to 83% for irinotecan and 66% for raltitrexed at level VII. Lethargy was
therefore the DLT, and level VII the MTD. Pharmacokinetic data showed no measurable drug interaction; 6/30 patients (20%) had objective
responses. This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m–2 and
raltitrexed 3.0 mg m–2. © 2000 Cancer Research Campaign
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renal and hepatic function; written informed consent.
Exclusion criteria were: previous treatment with topoisomerase
I inhibitor; chronic enteropathy; symptomatic cerebral metastasis
or leptomeningeal carcinomatosis; unresolved bowel obstruction;
pregnancy; previous malignant disease (except adequately treated
carcinoma in situ of the cervix uteri or basal cell carcinoma of the
skin).
Pre-treatment evaluation
Prior to entry, patients were evaluated with a physical examina-
tion. An ECG, chest X-ray and CT scan of thorax abdomen and
pelvis were carried out on all patients. Other radiological investi-
gations were carried out if indicated. A full blood count, renal
function tests, liver function tests and prothrombin time were also
performed.
Treatment schedule
Irinotecan was administered as a 30-min infusion on day 1
followed after 30 min by a 15-min infusion of raltitrexed. This
cycle was repeated at 21-day intervals. The dose escalation
schedule is shown in Table 1. A minimum of three patients were
recruited to each dose level, and escalation to the next level was
carried out when all three had been observed for a minimum of 2
weeks. The initial design was for the level below MTD to be
expanded to six patients. Due to the unusual pattern of toxicities
seen, however, the MTD dose level was expanded to six patients,
and 12 patients were treated at the level below MTD. Patients
received six cycles of treatment subject to favourable response.
Further cycles could be administered at the investigators’ discre-
tion if there was evidence of continuing clinical benefit.
Pharmacokinetic measurements
Blood was taken for pharmacokinetic studies after the first cycle 
of treatment at the following sampling times: before irinotecan
administration and then 15, 25, 35, 40 and 45 min; 1, 1.5, 1.75, 2,
2.5, 4.5, 7.5, 9, 13.5, 25.5, 49.5, 73.5, 145.5, 313.5 and 481.5 h
after the start of the irinotecan infusion. Irinotecan and SN38 were
measured by reversed-phase HPLC using a precipitation step by 
an acetonitrile-methanol mixture (50/50 v/v) containing the
internal standard (camptothecin), and a fluorescence detection at
excitation and emission wavelengths of 355 nm and 515 nm
respectively for irinotecan, and 388 nm and 540 nm for SN-38.
Raltitrexed concentrations were measured by radioimmunoassay
(Aherne et al, 1998). Pharmacokinetic analysis was performed
using WinNonlin software. The calculation of kinetic parameters
was performed using a 2- or 3-compartment open model for
irinotecan, and a non-compartmental analysis for its metabolite
SN-38 and raltitrexed. The following parameters were evaluated:
maximum plasma concentration (Cmax); area under the plasma
concentration-time curve (AUC); total body clearance (Cl);
volume of distribution at steady state (Vss) and terminal half-life
(t1/2).
Evaluation and management of toxicity
No prophylactic antidiarrhoeal treatment was given. Patients who
suffered from the cholinergic syndrome (an acute toxicity of
irinotecan, consisting of some or all of diarrhoea, hypersalivation,
lachrymosis, visual disturbance, diaphoresis and abdominal
cramps) were treated with atropine 250 mg by subcutaneous injec-
tion, and pretreated with this for each subsequent course. Patients
were seen weekly while on treatment. Toxicities were graded
according to the NCI common toxicity criteria (NCI-CTC).
Delayed diarrhoea was treated with high-dose loperamide: patients
were instructed to take 2 mg of loperamide at the onset of diar-
rhoea, and to take a further 2 mg every 2 h for at least 12 h after 
the last loose stool. Any patient experiencing concomitant
vomiting was hospitalized to prevent dehydration. If diarrhoea
persisted for more than 24 h, patients were treated with
ciprofloxacin 250 mg b.i.d. In the case of diarrhoea persisting for
more than 48 h the patient would be admitted to hospital for
parenteral support. All patients with febrile neutropaenia were
admitted to hospital and treated with intravenous antibiotics.
Doses of both irinotecan and raltitrexed were reduced by 20% if
any of the following occurred: grade 4 neutropenia; grade 3
neutropenia with fever; grade 3 or 4 diarrhoea. If day 22 absolute
neutrophil count was less than 1.5 ´ 109 l–1 or platelet count less
than 100 ´ 109 l–1, treatment was delayed up to a maximum of 2
weeks. In the case of myelosuppression lasting more than 5 weeks
from the date of treatment, the patient was withrawn from the
study. All patients were treated under the auspices of the GI unit at
the Royal Marsden Hospital, and the protocol was approved by the
hospital’s committee for clinical research and research ethics
committee.
Evaluation of response
Responses were evaluated according to standard WHO criteria.
Follow up CT scan evaluation was carried out after alternate treat-
ment cycles. Clinical evaluation and assessment of symptoms was
carried out prior to each treatment cycle.
Statistical methods
The results presented consist largely of a descriptive analysis. In
addition, Kaplan-Meier curves (Kaplan and Meier, 1958) were
generated for overall and progression-free survival, and median
time to disease progression (TTP) and overall survival (OS) calcu-
lated.
RESULTS
Between September 1996 and April 1998, 34 patients entered the
study (Table 2). One registered patient developed a fever prior to
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Table 1 Dose escalation scheme
Dose level Irinotecan dose (mg m–2) Raltitrexed dose (mg m–2)
I 175 2.6
II 200 2.6
III 250 2.6
IV 300 2.6
V 350 2.6
VI 350 3.0
VII 400 2.6starting treatment. By the time his fever had settled, his bilirubin
had risen to unacceptably high levels and he was excluded from
the study and subsequent analysis. All the other patients were
evaluable for toxicity. All had previously been treated with 5-FU-
based chemotherapy (5/33 had received adjuvant treatment 7–27
months before relapse and 28/33 had received prior chemotherapy
for advanced disease). Patients had received a median of 1 line of
prior treatment: 27/33 (82%) had received an infusional 5-FU
regimen, while 6/33 had been treated with bolus 5-FU/LV. Of the
evaluable patients, 11/25 (44%) had previously had objective
responses to 5-FU. 261 cycles were given (median five per patient,
range 1–33) all of which were assessable for toxicity (Table 3).
Toxicity
There were no treatment-related deaths. Toxicities are summarized
in Tables 4 and 5. Grade 4 neutropenia was seen in six patients, at
dose levels I (two patients), IV, VI (two patients) and VII. It was
never seen following the first cycle of treatment and was therefore
not dose-limiting. Duration of neutropaenia ranged from 3–8 days.
In four cases it was associated with fever requiring hospital admis-
sion: two patients developed Hickman line-related septicaemia
which resolved on removal of the line and antibiotic therapy; one
patient developed Klebsiella pneumoniae septicaemia and
responded to standard antibiotic treatment; the other patient was
admitted with fever, lethargy and grade 2 diarrhoea following
cycle 3. No pathogens were isolated from blood, urine or faeces
and he made an uneventful recovery following administration of
intravenous antibiotics. In one case, grade 4 neutropenia was
accompanied by grade 2 diarrhoea and stomatitis in the absence of
fever. The patient was admitted to hospital, treated with supportive
therapy and intravenous antibiotics, and recovered rapidly. One
other patient was found to have asymptomatic grade 4
neutropaenia on a routine blood count. Of these patients, two
received no further treatment and the other four had no further
neutropaenia episodes following dose reduction. Grade 3 throm-
bocytopenia was seen after two of 261 courses (one at dose level I,
one at dose level VI), grade 3 anaemia occurred after 1 of 261
cycles. There were no incidences of grade 4 anaemia or thrombo-
cytopenia.
Mild (grade 1–2) diarrhoea occurred after 45 of 261 courses
(15%). Grade 3 or 4 diarrhoea was only seen in four patients, all at
dose levels VI and VII. Even at these dose levels, it was only seen
after 3 of 45 (7%) and 1 of 33 (3%) treatment cycles respectively.
In one patient it was associated with neutropenia (grade 2) and
fever. Lethargy was graded as mild, moderate or severe (grades
1–3). Increasingly severe lethargy was seen at higher dose levels.
Nine of 12 patients at dose level VI and 5/6 patients at dose level
VII experienced severe (grade 3) lethargy. At dose level VII, the
onset of symptoms was earlier (with 3/6 patients experiencing
lethargy following their first treatment cycle, compared with 4/12
at level VI and only one patient at lower dose levels) and more
prolonged. Grade 3 lethargy was therefore defined as a DLT. The
number of patients experiencing severe lethargy was of concern,
and dose levels VI and VII were therefore expanded to 12 and 6
patients respectively, with the aim of further characterizing this
toxicity. In six of the nine patients experiencing grade 3 lethargy at
dose level VI, the symptom was due to progressive disease.
Despite the absence of dose reduction, four of the nine patients’
lethargy improved on treatment and subsequently returned at the
time of disease progression, suggesting a disease-related phenom-
enon. Two further patients had disease which progressed rapidly
after two cycles of treatment, and it was felt that their lethargy was
principally attributable to disease. In only two patients at this dose
level was lethargy clearly drug-related. In one further patient,
lethargy was associated with disease progression, but improved on
cessation of treatment, and this patient was regarded as having
drug-related lethargy. At dose level VII, five out of six patients
experienced grade 3 lethargy, and in four the symptom was clearly
attributable to toxicity, with significant improvement on cessation
or dose reduction.
Mild nausea was common (27/33 patients), but easily controlled
with standard anti-emetic medication. Elevation of hepatic
transaminases occurred in most patients but tended to improve in
subsequent courses and was not dose-limiting. In one patient
transaminitis failed to resolve, and he was withdrawn from the
study. CT scan after a further two cycles of irinotecan showed
progressive disease in the liver, which was felt to be responsible.
One patient developed lower limb cellulitis secondary to
raltitrexed, and was treated with irinotecan alone for 6 cycles. This
patient subsequently received a further four cycles of the
irinotecan/raltitrexed combination without complication. Two
patients developed grade 1 rises in serum creatinine, necessitating
dose delay. One of these had a hydronephrosis secondary to peri-
toneal metastases. Following ureteric stenting, his creatinine
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Table 2 Patient characteristics
Characteristic Number
Sex
Male 24
Female 9
Age (years)
Median 56
Range 38–71
PS (WHO)
01 1
11 9
23
Primary site
Colon 14
Rectum 17
Oesophagus 1
Stomach 1
Prior chemotherapy lines
(including adjuvant therapy)
12 4
29
Table 3 Patients and courses per dose level
Dose level No. of patients No. of courses (range)
I 3 43 (3–33)
II 3 41 (12–16)
III 3 33 (9–12)
IV 3 49 (2–30)
V 3 13 (2–7)
VI 12 45 (1–9)
VII 6 37 (2–15)
TOTAL 33 261 (1–33)improved sufficiently to allow further chemotherapy. The other
patient was found to have a creatinine clearance of 67 ml min–1,
and her serum creatinine when measured 7 days later was normal.
She therefore continued treatment as scheduled. A summary of
first-cycle toxicities by dose level is shown in Table 6. It was
concluded that the DLT for the combination of irinotecan and
raltitrexed is lethargy, and that the MTD is irinotecan 400 mg m–2
and raltitrexed 2.6 mg m–2 3-weekly. The recommended doses for
phase II evaluation were set at irinotecan 350 mg m–2 and
raltitrexed 3.0 mg m–2.
Dose intensity
Calculations were made from the first six treatment cycles. Dose
delays were seen after 24/143 cycles (17%). Reasons for delay
were: raised hepatic transaminases (8/24); neutropenia (5/24);
lethargy (4/24); infection without neutropenia (2/24); elevated
serum creatinine (2/24); patient request (2/24) and subacute bowel
obstruction (1/24). Median dose delay was 7 days at dose levels I-
VI and 12 days at level VII. Six patients required dose reduction.
Dose intensity (DI) for each drug was calculated as a percentage of
intended. DI approximated 100% at levels I-VI. At level VII,
raltitrexed DI fell to 66% and irinotecan DI was only 83%,
providing further evidence for this being the MTD.
Irinotecan pharmacokinetics
Pharmacokinetic data for irinotecan was obtained in 26 patients
(Table 7). The total plasma clearance of irinotecan was relatively
stable over the seven investigated dose levels with an overall
mean value of 12.4 l h–1 m–2. A slightly higher interpatient vari-
ability was observed for the other parameters. For SN-38,
maximal concentrations were mainly observed within the 60 min
following the end of i.v. infusion, and the apparent terminal half-
life was stable over the administered dose range with a mean
value of 11.1 h.
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Table 4 NCI-CTC grade 1–2 toxicity by dose level (all cycles)
Dose level NCI-CTC toxicity grade 1–2
Lethargy
(mild–moderate) Neutropenia Diarrhoea Nausea Transaminitis
I 3/3 0/3 3/3 2/3 1/3
II 3/3 1/3 0/3 3/3 2/3
III 2/3 0/3 3/3 3/3 1/3
IV 1/3 0/3 3/3 3/3 2/3
V 3/3 1/3 2/3 2/3 0/3
VI 2/12 3/12 6/12 11/12 6/12
VII 0/6 2/6 4/6 3/6 3/6
Table 5 NCI-CTC grade 3–4 toxicity by dose level (all cycles)
Dose level NCI-CTC toxicity grade 3–4
Lethargy
(severe) Neutropenia Diarrhoea Nausea Transaminitis
I 0/3 2/3 0/3 0/3 1/3
II 0/3 0/3 0/3 0/3 1/3
III 1/3 1/3 0/3 0/3 1/3
IV 2/3 3/3 0/3 0/3 0/3
V 0/3 0/3 0/3 0/3 2/3
VI 9/12 6/12 3/12 1/12 5/12
VII 5/6 2/6 1/6 1/6 3/6
Table 6 First-cycle toxicity
Dose level Lethargy G3 Neutropenia G4 Diarrhoea G3–4 Total no. of patients
experiencing DLT
I 0/3 0/3 0/3 0
II 0/3 0/3 0/3 0
III 0/3 0/3 0/3 0
IV 1/3 0/3 0/3 1
V 0/3 0/3 0/3 0
VI 4/12a 0/12 2/12 5b
VII 3/6 0/6 1/6 3
aDrug-related toxicity in 2/4 patients; bDrug-related toxicity in 3/12 patientsRaltitrexed pharmacokinetics
Pharmacokinetic data was obtained from 27 patients (Table 8).
There were minor variations in individual parameters with
increasing doses of irinotecan, however Cl was stable at 3.1 l h–1
over all dose ranges, as was the t1/2 at 291 h.
Survival
Twenty-six patients have died and two are lost to follow-up. With
a median follow-up of 14.8 months, median survival is 9.3
months. Median progression-free survival is 4.8 months.
Response
Thirty patients had measurable disease. Of these there were six
partial responses, giving an objective response rate of 20%.
Median response duration was 6.9 months. Thirteen patients
(43%) had stable disease confirmed by CT scans 6 weeks apart.
The median time to disease progression (TTP) in these patients is
7.7 months. Eleven patients (37%) progressed, including both of
the patients with oesophagogastric cancer. Responses were seen at
dose levels I, II, IV, VI (two responses) and VII.
DISCUSSION
Combination therapy is likely to represent the future standard of
care for advanced colorectal cancer. Phase I studies of irinotecan in
combination with 5-FU have demonstrated that effective doses of
the two drugs may be given together despite the potential for over-
lapping toxicities (Saltz et al, 1996). Recently completed phase III
studies have shown that this combination provides improved
response rates when compared to 5-FU alone (Saltz et al, 1999;
Douillard et al, 1999). This study aimed to assess the potential of
the similar combination of irinotecan and raltitrexed. The in vitro
data showing synergy when cells were exposed to SN-38 before
raltitrexed provided the rationale for giving the drugs in this
sequence. One preclinical study suggested that this synergy was
further potentiated by a 24 h interval between administration of the
drugs (Aschele et al, 1998), however same day administration was
chosen for this trial for patient convenience. For irinotecan, 
the pharmacokinetic results were consistent with previous
monotherapy data (Abigerges et al, 1995). Although total body
clearance was slightly lower at the highest dose investigated of
400 mg m–2 (12.9 vs 14.8 l h–1 m–2), other parameters were compa-
rable (Vss 146 vs 150 l m–2 and terminal t1/2 10.7 vs 12.0 h). SN-38
t1/2 was also similar to that determined in 168 phase I cancer
patients treated with irinotecan alone (11.1 vs 10.6 h). SN-38
Cmax and AUC values were in the same range as with irinotecan
monotherapy (e.g. at the highest dose tested 0.117 vs 0.094 mg ml–1
and 0.76 vs 0.67 mg h–1 ml–1 respectively) (Chabot et al, 1995).
Despite the administration of raltitrexed, SN-38/irinotecan AUC
ratio values were roughly stable over the tested dose range, and
were close to those observed in monotherapy (overall mean value
of 2.4 vs 3.1%) (Abigerges et al, 1995). There is less published
data available for raltitrexed. However in this trial, despite patient-
to-patient variability, results were similar to those obtained with
single-agent treatment. For instance at 3.0 mg m–2, mean values
for raltitrexed Cmax and AUC were 772 vs 737 ng ml–1 and 2480
vs 2342 ng h–1 ml–1 respectively, when compared to data obtained
from the administration of 14C labelled raltitrexed (Beale et al,
1998). At this dose level, values for raltitrexed clearance (2.41 vs
150 HER Ford et al
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Table 7 Pharmacokinetic parameters for irinotecan and SN-38
Dose No. of Irinotecan SN-38 SN-38/irinotecan
level patients AUC ratio (%)
Cmax
a AUC CI Vss t1
2 terminal Cmax
b AUC
(mg ml–1 (mg h ml–1) (l h–1 m–2) (l m–2) (h) (mg ml–1)( mg h ml–1)
I 3 3.53 ± 0.07 13.1 ± 1.6 11.7 ± 1.6 63 ± 9 5.5 ± 2.2 0.048 ± 0008 0.27 ± 0.12 2.1 ± 0.8
II 3 4.70 ± 0.56 16.0 ± 5.4 11.6 ± 3.5 9.8 ± 1.2 9.8 ± 2.2 0.074 ± 0.048 0.52 ± 0.25 3.2 ± 0.6
III 3 5.92 ± 1.15 14.6 ± 1.8 15.0 ± 2.0 11.7 ± 7.2 11.7 ± 7.2 0.060 ± 0.014 0.33 ± 0.03 2.3 ± 0.1
IV 3 5.98 ± 4.22 22.6 ± 6.2 12.6 ± 3.4 11.4 ± 5.0 11.4 ± 5.0 0.071 ± 0.017 0.44 ± 0.10 2.1 ± 0.8
V 3 4.89 ± 1.03 26.6 ± 11.4 12.5 ± 4.6 7.2 ± 0.9 7.2 ± 0.9 0.057 ± 0.015 0.78 ± 0.35 2.9 ± 0.3
VI 6 5.43 ± 1.00 29.0 ± 12.2 11.3 ± 3.1 9.6 ± 3.9 9.6 ± 3.9 0.100 ± 0.016 0.58 ± 0.23 2.1 ± 0.8
VII 5 5.41 ± 2.60 27.0 ± 7.4 12.9 ± 2.7 10.7 ± 6.6 10.7 ± 6.6 0.117 ± 0.116 0.76 ± 0.39 2.7 ± 0.9
aestimated Cmax at the end of i.v. infusion; bobserved Cmax.
Table 8 Pharmacokinetic parameters for raltitrexed
Dose level No. of patients Cmax AUC CI Vss t1
2 terminal
(ng ml–1) (ng h ml–1) (l h–1) (l) (h)
I 3 561 ± 78 1711 ± 607 3.01 ± 0.77 40.7 ± 14.8 222 ± 102
II 3 420 ± 72 1440 ± 697 4.70 ± 1.9 27.3 ± 6.1 190 ± 107
III 3 291 ± 32 1464 ± 305 3.36 ± 0.58 60.2 ± 31.4 345 ± 62
IV 3 676 ± 185 1814 ± 381 2.83 ± 0.86 32.3 ± 15.5 348 ± 171
V 3 736 ± 161 2520 ± 1586 2.50 ± 1.4 30.2 ± 6.7 403 ± 99
VI 6 772 ± 204 2480 ± 698 2.41 ± 0.90 25.8 ± 9.4 296 ± 16
VII 6 574 ± 143 1503 ± 177 3.34 ± 0.86 43.8 ± 9.6 261 ± 732.48 l h–1 and t1/2 (296 vs 257 h) were also consistent with data
from this study. These data suggest that the concomitant adminis-
tration of raltitrexed and irinotecan according to this schedule does
not modify the behaviour of either drug.
Since this study was completed, work has been published
showing that the AUC for raltitrexed may be approximately doubled
in patients with measured creatinine clearance less than 65 ml min–1
(Judson et al, 1998). Entry into this study was based on normal
serum creatinine (or normal measured creatinine clearance if serum
creatinine was elevated). In the light of this information, however,
patients’ calculated creatinine clearance (using the Cockroft and
Gault formula) was retrospectively examined. Only one patient had
a pre-treatment creatinine clearance less than 65 ml min–1 (44 ml
min–1), and this patient did not experience any toxicity. One patient
with grade 3 diarrhoea had a fall in creatinine clearance from 68 to
55 ml min–1 following his first cycle of treatment, and did develop
asymptomatic and short-lived grade 4 neutropenia following cycle
3. Whether or not these events are related is uncertain, and all other
patients experiencing grade 3 or 4 toxicity had normal calculated
creatinine clearances before and after treatment. Nevertheless, it is
now recommended that patients receiving raltitrexed have creatinine
clearance calculated prior to each course of treatment and appro-
priate dose modifications adopted in the case of values less than 
65 ml min–1, and this recommendation should also be applied to the
use of the drug in combination. Similarly, the clearance of irinotecan
is predominantly liver-dependent (Raymond et al, 1999), and there
is a theoretical possibility that, although it seldom if ever causes
elevation of bilirubin, the transaminitis induced by raltitrexed might
affect irinotecan pharmacokinetics. There was no association in this
study between transaminitis and other toxicities. In addition, toxicity
overall was no greater than might have been expected from single-
agent irinotecan, despite the high incidence of transaminitis seen
(85% of all patients).
Although pharmacokinetics were not tested for the second and
subsequent cycles, and it is impossible therefore to know whether
or not pharmacokinetics are affected, there is no evidence that
raltitrexed-induced transaminitis increases susceptibility to toxi-
city from this combination.
In this study it is notable that diarrhoea and myelosuppression,
which are the DLT for both drugs as single agents, were not a
major feature of the combination. The DLT of this combination is
lethargy. This may occur at any dose, but at the higher dose levels,
especially level VII, was often much more severe and prolonged.
When the protocol was drawn up there was no CTC scale for
lethargy, although the severe lethargy seen at these levels
corresponds to grade 4 toxicity in the latest CTC revision (CTC
version 2.0, National Cancer Institute, Bethesda, January 1998).
Unfortunately, it is often difficult to differentiate lethargy caused
by disease progression from that caused by the drugs themselves,
and this inevitably introduces an element of subjectivity into the
interpretation of the results. To reduce this as far as possible grade
3 (severe) lethargy was therefore defined as a DLT, regardless of
cause. When interpreting the palliative benefits of the regimen,
however, it is important to note that of nine cases of grade 3
lethargy seen at dose level VI, six were associated with simulta-
neous disease progression. Only two patients at this dose level had
grade 3 lethargy which was clearly attributable to the study
regimen, and indeed in four of the other cases (none of whom had
a dose reduction) lethargy improved in subsequent cycles, only to
re-emerge at the time of disease progression. By contrast, at dose
level VII only one patient did not suffer from severe lethargy, and
of the five who did, only one had associated disease progression.
The remaining four patients’ lethargy improved on cessation of
treatment or following dose reduction. It was to evaluate this toxi-
city further that dose levels VI and VII were expanded to 12 and 6
patients respectively, and we are satisfied that although severe
lethargy may be seen at dose level VI, it is only dose-limiting at
level VII. In view of the phase I data showing increased lethargy
with raltitrexed at doses above 3.0 mg m–2 (Clarke et al, 1996) it
was decided not to further escalate the raltitrexed dose. Further
support for level VII as the MTD is provided by the dose intensity
figures, with a major fall in DI at this dose level. The recom-
mended dose for phase II evaluation was therefore set at level VI
(irinotecan 350 mg m–2 and raltitrexed 3.0 mg m–2) despite the
absence of conventional DLT.
The definition of MTD chosen for this study was the dose level
at which 50% of patients experienced the same DLT. This appar-
ently aggressive definition was chosen because experience in phase
I studies of raltitrexed had shown that a variety of sporadic grade 3
and 4 toxicities could occur at lower dose levels (Clarke et al, 1996)
and we did not wish to terminate the trial prematurely following the
occurrence of three different non dose-related toxicities. In retro-
spect, a more conventional definition may have been appropriate
for the study. Nevertheless, the MTD would in fact have been the
same using either definition, and there is therefore no suggestion
that the choice of definition affected the validity of the results.
There was evidence of anti-tumour activity, with an ORR of 20%
in predominantly 5-FU-refractory patients, and a significant
proportion of patients (43%) had disease stabilization, often for a
prolonged period. Another issue raised by the study is the optimum
duration of treatment. Eleven patients on this study (33%) received
more than eight cycles of treatment. Indeed, one patient received 33
cycles without a partial response prior to disease progression.
Interestingly, he was being treated at low doses of the combination
(dose level I). Preclinical models have suggested that irinotecan has
an anti-angiogenic effect (O’Leary et al, 1999), and this is one
possible explanation. At the moment there are no guidelines as to
the optimum duration of treatment with irinotecan, although clin-
ical studies are addressing this question. Related to this is the rele-
vance of disease stabilization as a therapeutic goal. Over 40% of
patients in this trial achieved stable disease, and although this may
merely indicate a subset of patients with indolent tumours, the
median TTP of 7.7 months in this group compared to 6.9 months in
responding patients does suggest significant clinical benefit.
In conclusion, the combination of irinotecan and raltitrexed is
active and well tolerated, and the 3-weekly schedule is convenient
for patients. This combination merits further investigation, and a
phase II study in colorectal cancer has been initiated at the doses of
irinotecan 350 mg m–2 and raltitrexed 3.0 mg m–2 every 3 weeks.
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